PL428992A1 - Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą - Google Patents

Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą

Info

Publication number
PL428992A1
PL428992A1 PL428992A PL42899219A PL428992A1 PL 428992 A1 PL428992 A1 PL 428992A1 PL 428992 A PL428992 A PL 428992A PL 42899219 A PL42899219 A PL 42899219A PL 428992 A1 PL428992 A1 PL 428992A1
Authority
PL
Poland
Prior art keywords
degree
determining
gal
patient
protein
Prior art date
Application number
PL428992A
Other languages
English (en)
Other versions
PL240124B1 (pl
Inventor
Ewa Łucja Stępień
Agnieszka Kamińska
Original Assignee
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński filed Critical Uniwersytet Jagielloński
Priority to PL428992A priority Critical patent/PL240124B1/pl
Priority to PCT/PL2020/050020 priority patent/WO2020171724A1/en
Publication of PL428992A1 publication Critical patent/PL428992A1/pl
Publication of PL240124B1 publication Critical patent/PL240124B1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób określanie stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą, charakteryzuje się tym, że w próbce moczu od pacjenta cierpiącego na cukrzycę określa się stężenie białka gal-3, przy czym: wartość stężenia białka gal-3 w moczu poniżej 11,06 ng/mL świadczy o istnieniu u tego pacjenta stopnia uszkodzenia nerek odpowiadającego umiarkowanie ciężkiemu lub ciężkiemu obniżeniu współczynnika przesączania kłębuszkowego eGFR poniżej 44 ml/min/1,73 cm2, wartość stężenia białka gal-3 w moczu powyżej 11,06 ng/mL świadczy o istnieniu u tego pacjenta stopnia uszkodzenia nerek odpowiadającego umiarkowanemu, niewielkiemu lub łagodnemu obniżeniu współczynnika przesączania kłębuszkowego eGFR do wartości powyżej 44 ml/min/1,73 cm2.
PL428992A 2019-02-21 2019-02-21 Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą PL240124B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL428992A PL240124B1 (pl) 2019-02-21 2019-02-21 Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą
PCT/PL2020/050020 WO2020171724A1 (en) 2019-02-21 2020-02-21 Method of determination of the degree of renal damage occurring in subjects with diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL428992A PL240124B1 (pl) 2019-02-21 2019-02-21 Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą

Publications (2)

Publication Number Publication Date
PL428992A1 true PL428992A1 (pl) 2020-08-24
PL240124B1 PL240124B1 (pl) 2022-02-21

Family

ID=70334017

Family Applications (1)

Application Number Title Priority Date Filing Date
PL428992A PL240124B1 (pl) 2019-02-21 2019-02-21 Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą

Country Status (2)

Country Link
PL (1) PL240124B1 (pl)
WO (1) WO2020171724A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014055687A1 (en) * 2012-10-05 2014-04-10 Hitachi Chemical Co., Ltd. Urine exosome mrnas and methods of using same to detect diabetic nephropathy

Also Published As

Publication number Publication date
WO2020171724A1 (en) 2020-08-27
PL240124B1 (pl) 2022-02-21

Similar Documents

Publication Publication Date Title
WO2012040073A3 (en) Biomarkers of renal injury
Akbari et al. Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management
DE60329589D1 (de) Antikörper gegen den humanen "insulin-like" wachstumsfaktor
WO2007143098A8 (en) Hepatocyte growth factor (hgf) binding proteins
PL428992A1 (pl) Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą
EA202190302A1 (ru) Соединения 2,6-диаминопиридина
EP4684832A3 (en) Potassium-binding agents for treating hypertension and hyperkalemia
EA201991676A1 (ru) Ингибиторы nhe-опосредованного антипорта
WO2011089234A3 (en) Aqueous solution comprising 3 - quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease
HRP20231469T1 (hr) Poboljšani protokol za liječenje lupus nefritisa
PH12020551159A1 (en) Methods of treating subjects having diabetes with chronic kidney disease
BR112016029067A2 (pt) ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios?
EA200700273A1 (ru) Способ лечения гиперфосфатемии c использованием гидроксикарбоната лантана
Davenport Measuring residual renal function in dialysis patients: can we dispense with 24-hour urine collections?
RU2016147122A (ru) Применение серелаксина для снижения gdf-15
MX2007003094A (es) 4-(metilo ciclico condensado)-imidazol-2-tionas como agonistas alfa2 adrenergicos.
EP3441768A3 (en) Marker for statin treatment stratification in heart failure
WO2007022947A3 (de) 5-ring-heteroaromaten-verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
RU2016102202A (ru) Биологический маркер опухоли
Niri et al. Renal function and plasma renin activity as potential factors causing hyperkalemia in patients with thyroid carcinoma undergoing thyroid hormone withdrawal for radioactive iodine therapy
Brobak et al. The association between urinary sodium-potassium ratio, kidney function, and blood pressure in a cohort from the general population
Wyatt et al. Folic acid supplementation and chronic kidney disease progression
JOP20200046A1 (ar) طرق لعلاج أمراض مرتبطة بـtnf?
MX2024000251A (es) Efpeglenatida para reducir el riesgo de desarrollar enfermedad cardiovascular 0 disfunción renal.
MX2023014359A (es) Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico.